Shots:
- CARsgen reported that early clinical results of CT0596, in Pts with R/R MM, were shared in ASH’25. The company plans a P-Ib registrational study in 2026, following an IND submission expected in H2’25
- The P-I trial enrolled 8 pts with R/R MM who received CT0596, with a median of 4.5 prior therapy lines. Enrollment was independent of NKG2A expression. 6 received full-dose lymphodepletion, and 2 received reduced-dose lymphodepletion
- With a median follow-up of 4.14 mos., 6/8 pts achieved PR or better: 3 CR/sCR, 1 VGPR, and 2 PR. Five of six full-dose pts responded, and all six were MRD-negative at Wk 4. Pt 01 sustained sCR and MRD-negativity to 8 Mos; Pt 04 improved to PR with resolution of EMD after a second infusion. Safety was manageable
Ref: PRNewswire | Image: CARsgen Therapeutics | Press Release
Related News: Thermo Fisher Scientific’s EXENT System Receives the US FDA’s 510(k) Clearance to Aid Multiple Myeloma Diagnosis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
